Star Medical Supplies

DENK PHARMA

Featured products of Denk Pharma
metformin hydrochloride
Packing/Price
10 × 10's
MIMS Class
Antidiabetic Agents
ATC Classification
A10BA02 - metformin : Belongs to the class of biguanides. Used in the treatment of diabetes.
metformin hydrochloride
Packing/Price
10 × 10's
MIMS Class
Antidiabetic Agents
ATC Classification
A10BA02 - metformin : Belongs to the class of biguanides. Used in the treatment of diabetes.
nifedipine
Packing/Price
10 × 10's
MIMS Class
Calcium Antagonists
ATC Classification
C08CA05 - nifedipine : Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
nifedipine
Packing/Price
10 × 10's
MIMS Class
Calcium Antagonists
ATC Classification
C08CA05 - nifedipine : Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
Distributed by Star Medical Supplies
metformin hydrochloride
Packing/Price
10 × 10's
MIMS Class
Antidiabetic Agents
ATC Classification
A10BA02 - metformin : Belongs to the class of biguanides. Used in the treatment of diabetes.
metformin hydrochloride
Packing/Price
10 × 10's
MIMS Class
Antidiabetic Agents
ATC Classification
A10BA02 - metformin : Belongs to the class of biguanides. Used in the treatment of diabetes.
nifedipine
Packing/Price
10 × 10's
MIMS Class
Calcium Antagonists
ATC Classification
C08CA05 - nifedipine : Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
nifedipine
Packing/Price
10 × 10's
MIMS Class
Calcium Antagonists
ATC Classification
C08CA05 - nifedipine : Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.

Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in